Did Cardiac Amyloidosis Undermine HFpEF Trials?

(MedPage Today) -- One theory for why the medications tested in heart failure with preserved ejection fraction (HFpEF) trials have not shown efficacy: inclusion of too many unrecognized cases of cardiac amyloidosis (CA).
"The specific hemodynamic...